LYPLA2

Across TCGA pan-cancer cohorts, LYPLA2 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated LYPLA2 data layer compared with 24 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher LYPLA2 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated LYPLA2 expression acts as an unfavorable survival marker, although some lineages such as UCEC and PDAC show a favorable association.

UCEC, PDAC, and HNSC are the cancer types where LYPLA2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	DFS	Median	All	0.989	0.834	.002	46	view →
PDAC	DFS	Tertile	All	0.416	0.223	.009	12	view →
HNSC	DFS	Tertile	All	0.927	1.000	.007	8	view →
COAD	DFS	Median	IV	0.493	0.944	.031	6	view →
LUAD	DFS	Quartile	II,III,IV	0.662	0.488	.040	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

LYPLA2–UCEC (DFS)

Open the UCEC breakdown →